EGFR Mutation Test: Lung Cancer, Targeted Therapy, and Results

An EGFR mutation test examines cancer DNA or RNA for changes in the epidermal growth factor receptor gene. In non-small-cell lung cancer, especially adenocarcinoma, certain EGFR variants act as growth drivers and can make the tumor sensitive to EGFR-targeted medicines. The result may influence first-line treatment, treatment after progression, and testing of a new biopsy or blood sample when resistance develops. EGFR testing is not the same as measuring EGFR protein by immunohistochemistry, and a positive result must name the exact variant because exon 19 deletions, L858R, exon 20 insertions, and uncommon mutations do not all respond to the same drugs. Tissue remains the preferred source when an adequate biopsy is available, but plasma circulating tumor DNA can provide a faster or less invasive option. A negative plasma result cannot reliably exclude an EGFR mutation because some tumors release little DNA into the bloodstream. The report should be interpreted with the cancer type, stage, sample quality, assay coverage, and results for other lung-cancer biomarkers.

• EGFR testing is routinely important in advanced nonsquamous non-small-cell lung cancer and in selected earlier-stage cases.
• Exon 19 deletions and L858R are the most common sensitizing variants and often support EGFR tyrosine kinase inhibitor therapy.
• Exon 20 insertions form a separate group and require variant-specific treatment interpretation.
• A negative blood test may need follow-up tissue testing when the clinical need remains high.
• Resistance testing can identify changes such as T790M, C797S, MET amplification, or other bypass mechanisms.

Table of Contents

• What EGFR Testing Detects
• Who Should Be Tested
• Tissue, Plasma, and Test Methods
• How to Read an EGFR Result
• Treatment Meaning by Variant
• Testing After Progression
• Negative, Limited, and Uncertain Results

What EGFR Testing Detects

EGFR encodes a receptor tyrosine kinase on the cell surface. When its normal ligand binds, the receptor activates signals that regulate cell growth and survival. Some acquired EGFR mutations keep the signaling pathway active without the usual control. In a lung tumor, that altered receptor can become the main engine of cancer growth, creating a therapeutic vulnerability.

Clinical testing searches for somatic variants in tumor cells. These changes are usually not inherited and do not imply that relatives carry the same mutation. The specimen may be tumor tissue, cytology material, pleural fluid, cerebrospinal fluid in selected cases, or plasma cell-free DNA. A broader solid tumor NGS panel often evaluates EGFR together with ALK, ROS1, BRAF, KRAS, MET, RET, ERBB2, NTRK, and other actionable genes.

EGFR variants cluster in exons 18 through 21, which encode the kinase domain. Important groups include:

• Exon 19 deletions: In-frame deletions around amino acids E746 to A750 are common sensitizing alterations.
• L858R: A single amino-acid substitution in exon 21 and the other major classic sensitizing variant.
• G719X, L861Q, and S768I: Uncommon activating variants with drug sensitivity that can differ by allele and combination.
• Exon 20 insertions: A diverse group of in-frame insertions or duplications that usually behave differently from classic sensitizing variants.
• T790M: A resistance mutation historically associated with progression on earlier-generation EGFR inhibitors.
• C797S: A resistance change that can interfere with covalent binding of third-generation inhibitors.

The exact nomenclature matters. “EGFR positive” is too vague for treatment selection. A report should include the genomic change, protein change, exon, variant allele frequency when available, classification, and any assay limitations. Compound mutations should be listed separately because two changes on the same or different DNA molecules may affect response.

EGFR mutation testing differs from EGFR amplification and EGFR protein expression. Copy-number gain may be reported by some panels, but it is not interchangeable with a sensitizing kinase-domain mutation. Immunohistochemistry showing EGFR protein is also not an adequate substitute for molecular testing in lung adenocarcinoma.

Who Should Be Tested

Broad molecular testing is standard for most patients with advanced nonsquamous non-small-cell lung cancer. Testing should generally occur before systemic treatment begins when the patient is clinically stable enough to wait for results. Starting immunotherapy before driver testing is complete can complicate subsequent treatment and may expose a person with an actionable mutation to a less effective sequence or greater toxicity.

Patients with squamous histology may also be tested when clinical or pathologic features raise the chance of a targetable driver. Examples include never or light smoking history, younger age, small biopsy samples in which an adenocarcinoma component cannot be excluded, or mixed histology. Many centers increasingly use broad reflex testing rather than relying only on clinical predictors because actionable variants can occur outside classic demographic groups.

EGFR testing also has roles in earlier-stage disease. Resected or potentially resectable nonsquamous lung cancers may be tested when the result could affect adjuvant or perioperative treatment. The exact stage and treatment indication should be reviewed under current oncology guidance, since recommendations evolve as trial data and regulatory decisions change.

Testing may be ordered at several points:

1. At initial diagnosis of advanced disease
2. After surgery when adjuvant targeted therapy is being considered
3. At recurrence after earlier-stage treatment
4. At progression during EGFR-targeted therapy
5. When the original test was incomplete or used a narrow method
6. When a new lesion suggests histologic transformation or a second cancer

A small biopsy should be managed carefully so enough material remains for all required biomarkers. Sequential single-gene tests can consume tissue and delay results. Broad NGS often improves efficiency, although a rapid EGFR assay may be added when an urgent result is needed. A tumor molecular profiling test can also reveal co-mutations that influence prognosis or resistance.

Clinical features cannot replace testing. EGFR mutations are more frequent in never-smokers, women, people of East Asian ancestry, and adenocarcinoma, but they also occur in men, smokers, and people of every ancestry. Treatment decisions should rely on the tumor result rather than assumptions based on demographics.

Tissue, Plasma, and Test Methods

Formalin-fixed tumor tissue from a biopsy or surgical specimen is the usual reference sample. A pathologist confirms the diagnosis, estimates tumor content, and selects an area for extraction. Cytology cell blocks, fine-needle aspirates, pleural-fluid cell pellets, and other validated specimens may be suitable. Low tumor content can reduce sensitivity, so the report should note whether the specimen met quality thresholds.

Plasma testing analyzes circulating tumor DNA, or ctDNA, within cell-free DNA. It can shorten turnaround time, avoid an invasive biopsy, and sample DNA released from multiple tumor sites. It is particularly useful when tissue is unavailable, unsafe to obtain, exhausted, or too slow for an urgent decision. The broader principles of a liquid biopsy cancer test apply: a detected actionable variant is often informative, while a nondetected variant may reflect low shedding rather than true absence.

Sensitivity of plasma testing varies with disease burden and location. Extensive extracranial disease often sheds more ctDNA than small-volume, indolent, intrathoracic-only, or brain-dominant disease. A negative plasma test should therefore be followed by tissue testing when feasible and clinically necessary. Cerebrospinal fluid can be more informative than plasma for isolated central nervous system progression, but collection is reserved for selected situations.

Common laboratory methods include:

• Targeted PCR: Fast and sensitive for predefined common variants, but it can miss rare or complex alterations outside the assay menu.
• Digital PCR: Highly sensitive for a known hotspot such as T790M, but not comprehensive.
• DNA-based NGS: Detects many substitutions, deletions, insertions, and co-mutations in one assay.
• RNA-based NGS: More often used for fusions, but it may help characterize some expressed splice or insertion events.
• Sanger sequencing: Less sensitive than modern targeted methods and usually not preferred for low-tumor-content samples.

Exon 20 insertions are technically challenging because they are heterogeneous. An assay that tests only a few common insertions can produce false-negative results. The laboratory should validate coverage across the relevant region and report the exact insertion. Likewise, complex exon 19 changes can be missed by methods designed around one canonical deletion.

Variant allele frequency can support quality assessment but should not be equated directly with the percentage of cancer cells. Tumor purity, copy-number changes, normal-cell DNA, and plasma shedding all affect the value. A low VAF can still represent a true driver, especially in plasma, provided the call exceeds the assay’s validated threshold.

No fasting is required. For tissue testing, the main delay is often locating and transferring the block or unstained slides. Patients can help by giving the oncology team the date and location of prior biopsies. For plasma testing, blood should be collected in the laboratory’s approved tubes and processed within the validated time window to limit contamination from white-cell DNA.

How to Read an EGFR Result

The first step is to identify the precise variant and determine whether it is activating, resistance-associated, uncertain, or likely unrelated to treatment. The second is to confirm that the result came from the current cancer and an appropriate specimen. The third is to integrate stage, prior therapy, co-mutations, and current treatment guidance.

Finding	Usual interpretation	Clinical implication
Exon 19 deletion or L858R	Classic sensitizing EGFR driver	Supports use of an EGFR-targeted regimen in the appropriate stage and setting
G719X, L861Q, S768I, or compound uncommon variant	Activating but sensitivity varies	Requires allele-specific review and current guideline interpretation
Exon 20 insertion	Distinct activating subgroup with reduced sensitivity to many classic inhibitors	May support exon-20-directed treatment or trial options
T790M after earlier EGFR therapy	Acquired resistance mechanism	Historically supports third-generation EGFR inhibition when not already used
C797S or multiple resistance findings	Possible resistance to third-generation therapy	Needs review of mutation phase, co-alterations, tissue findings, and available trials
Variant of uncertain significance	Insufficient evidence for actionability	Should not be used alone to select or withhold targeted therapy

Coexisting mutations can affect behavior without erasing the EGFR driver. TP53 alterations are common and may be associated with a less favorable course. RB1 and TP53 together can raise concern for later small-cell transformation. PIK3CA, CTNNB1, MET amplification, ERBB2 amplification, and other changes may contribute to resistance. The report may classify them in tiers according to evidence and cancer type.

Mutual exclusivity is common but not absolute. A classic EGFR driver usually does not coexist as an equal founding driver with ALK, ROS1, or KRAS, yet rare co-alterations occur, especially after treatment or with highly sensitive assays. Apparent conflicts should prompt review of sample identity, VAF, tumor content, and whether one result could reflect clonal hematopoiesis or a separate tumor.

A positive plasma result for a recognized EGFR driver can often guide treatment without tissue confirmation when the clinical and pathologic context is clear. Tissue remains valuable for histology, PD-L1 testing, transformation, and mechanisms not well captured in plasma. A molecular result should never substitute for confirming that the patient has lung cancer and identifying its histologic type.

Treatment Meaning by Variant

Classic sensitizing mutations, mainly exon 19 deletions and L858R, predict benefit from EGFR tyrosine kinase inhibitors. Third-generation osimertinib has been a central option because it targets sensitizing mutations, has activity against T790M, and penetrates the central nervous system. Depending on stage, disease burden, prior treatment, and current approvals, clinicians may use osimertinib alone or consider combination strategies such as an EGFR inhibitor with chemotherapy or an antibody-based regimen.

Treatment selection is not based on the word “mutation” alone. Exon 20 insertions alter the kinase in a way that reduces sensitivity to standard doses of many earlier EGFR inhibitors. These tumors may be treated with agents or combinations developed for exon 20 insertions, and the available choices can depend on prior therapy and jurisdiction. The exact insertion should be retained in the record because emerging drugs may have different activity across variants.

Uncommon variants require more nuance. G719X, L861Q, and S768I can respond to certain EGFR inhibitors, but evidence is less extensive than for exon 19 deletion or L858R. Compound uncommon mutations may behave differently from a single alteration. Exon 18 E709X and other rare variants need review in a curated knowledge base or molecular tumor board rather than automatic assignment to a standard pathway.

Brain metastases influence drug choice because central nervous system activity matters. Osimertinib and some newer agents have meaningful intracranial activity, but local treatments such as stereotactic radiation or surgery may still be needed. The oncology team weighs symptoms, lesion size, number, prior radiation, extracranial control, and drug penetration.

EGFR mutation status also affects the sequencing of immunotherapy. EGFR-driven lung cancers generally derive less benefit from single-agent immune checkpoint inhibition than smoking-associated cancers without drivers, even when PD-L1 is high. Combining or sequencing immunotherapy and EGFR inhibitors can increase certain toxicities. Molecular results should therefore be available before committing to a treatment sequence whenever possible.

A negative result for sensitizing EGFR variants should not end biomarker evaluation. The tumor may carry an ALK alteration, ROS1 fusion, BRAF V600E, KRAS G12C, MET exon 14 skipping, RET fusion, ERBB2 mutation, NTRK fusion, or another actionable change. Broad testing avoids using a negative EGFR result as shorthand for “no targeted option.”

Testing After Progression

Resistance can develop even when an EGFR-targeted treatment works well initially. Progression may occur through an additional EGFR mutation, activation of another pathway, gene amplification, histologic transformation, or a mixture of mechanisms. The best next test depends on the pattern of progression and what information will change treatment.

A plasma NGS panel is often a practical first step because it can detect multiple resistance mechanisms quickly. A positive result may reveal MET amplification, EGFR C797S, acquired fusions, PIK3CA changes, or other alterations. However, plasma has limited ability to diagnose small-cell transformation and can miss copy-number changes or low-shedding disease. A tissue biopsy is especially important when progression is rapid, the clinical behavior changes, neuroendocrine markers rise, or transformation would alter therapy.

T790M was the dominant resistance mechanism after first- or second-generation EGFR inhibitors and remains clinically relevant in patients who have not received a third-generation drug. After first-line osimertinib, resistance is more diverse. C797S can prevent osimertinib binding. MET amplification is a common bypass mechanism and may lead to combination approaches in trials or selected clinical settings. The separate MET exon 14 skipping test should not be confused with testing for acquired MET amplification; they are different alterations with different biology.

The phase of compound mutations can matter. If C797S and T790M are on the same allele, treatment implications differ from mutations on opposite alleles. Routine reports do not always establish phase, especially at low VAF. Specialized analysis or repeat tissue testing may be needed.

Not every new mutation is the cause of progression. Some low-level findings are passengers or subclones. The treating team should compare current and baseline results, consider VAF changes, and match the mechanism to the treatment pressure. A molecular tumor board can help when several plausible resistance findings coexist.

Oligoprogression, in which only one or a few sites grow while the rest remain controlled, may be managed with local therapy while continuing the EGFR inhibitor. In that situation, immediate broad resistance testing may or may not change care. By contrast, widespread progression usually prompts systemic reassessment.

Negative, Limited, and Uncertain Results

A negative result means no reportable EGFR variant was found within the assay’s tested regions and sensitivity. It does not prove that the tumor is EGFR wild type. False-negative results can occur when tumor content is low, the sample is exhausted or degraded, the plasma ctDNA fraction is low, or the assay does not cover the relevant rare insertion or complex deletion.

The report should be checked for qualifiers such as “quantity not sufficient,” “low tumor fraction,” “limited panel,” or “no variants detected above 0.5% VAF.” A technically successful broad NGS result with adequate tumor content provides stronger reassurance than a negative rapid assay on a scant sample. When the result is unexpected, pathology and molecular teams can review the block and determine whether another specimen is better.

A variant of uncertain significance is not a treatment marker. EGFR contains many rare changes that have not been validated as activating or drug-sensitive. Computer predictions and isolated case reports may generate hypotheses, but standard treatment should not be selected solely from a VUS. Reclassification may occur as functional and clinical evidence grows.

A result can also be “nonactionable” because the detected alteration is outside the approved or guideline-supported setting, not because it is biologically irrelevant. Clinical trials may be appropriate for rare variants, resistance mechanisms, or tumors that have exhausted standard options.

Questions to ask after receiving the report include:

• Was the test performed on tissue, plasma, or another fluid?
• Did the assay cover all EGFR exons and insertion types relevant to lung cancer?
• Was tumor content or ctDNA fraction adequate?
• Is the exact variant sensitizing, resistant, uncertain, or incidental?
• Were other actionable lung-cancer genes tested at the same time?
• Does the result apply to first-line treatment, adjuvant treatment, or resistance after progression?
• Would a repeat biopsy provide histology or information that plasma cannot?

Treatment should not be delayed unnecessarily, but it should also not begin from an incomplete biomarker picture when a short wait can produce a safer, more effective plan. The oncology team can use rapid testing, broad NGS, and parallel tissue and plasma strategies to balance speed with completeness.

Turnaround time is worth discussing before the sample is collected. Rapid targeted assays may return in several days, while comprehensive tissue profiling can take one to three weeks after the laboratory receives an adequate specimen. Delays can be longer when blocks must be transferred from another hospital, the first sample fails quality control, or additional pathology review is required. Parallel plasma testing can sometimes provide an earlier actionable result while tissue testing continues. Patients should keep a copy of the full report, not only a portal message that says “positive” or “negative,” because the exact variant may remain important years later when new treatments or trials become available.

References

• Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2023 (Guideline)
• ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer 2022 (Consensus Statement)
• Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer 2021 (Consensus Statement)
• Update 2025: Management of Non-Small-Cell Lung Cancer 2025 (Review)
• Expanding Broad Molecular Reflex Testing in Non-Small Cell Lung Cancer to Early-Stage Disease 2024 (Review)
• Pan-Tumor Analytical Validation and Osimertinib Clinical Outcomes Using a Plasma-Based Comprehensive Genomic Profiling Assay 2024 (Clinical Study)

Disclaimer

EGFR results must be interpreted by the treating oncology and pathology teams using the exact variant, cancer stage, prior treatment, and assay limitations. Drug indications and preferred regimens can change, and this information does not replace current prescribing guidance or individualized care. New or worsening shortness of breath, chest pain, neurologic symptoms, or severe treatment effects require prompt medical evaluation.